INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a growing epidemic: in the United States of America alone, nearly 25.8 million people (approx 8.3% of the total population) have the disease. 1 Estimates have placed the global prevalence of the disease at around 217 million. 2 The consequence to the individual of prolonged exposure to hyperglycemia is a marked increase in the risk of mortality and morbidity, with an associated reduction in life expectancy of around [12] [13] years. 3 Diagnosis usually occurs some time after development of the disease and they have often already experienced occult pathology by the time patients receive a diagnosis. Early adoption of an aggressive approach to disease management improves patient outcome, with marked reductions in morbidity and mortality. [4] [5] [6] The first line approach to treatment is through lifestyle modification. 7 However, T2DM
is progressive in nature, and lifestyle changes sufficient to halt the disease are difficult to achieve. Intense efforts by patients and the healthcare team frequently fail. Similarly, most conventional antidiabetic drugs (eg, metformin, sulfonylureas etc.) often fail to slow the progression of T2DM, despite the availability of a broad range of agents employing different mechanisms of action. [7] [8] [9] The progressive nature of the disease and how it overwhelms available therapies was highlighted in the UKPDS study;
suggesting that fewer than half of all patients actually achieve adequate levels of disease control. 4, 5 There is a recognized need for new treatment options for T2DM. Characterization of the 
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As plasma glucose concentrations increase, the filtered glucose load increases in a linear manner. When the rate of glucose entering the nephron rises above 260-350 mg/min/1.73 m 2 ,
for example in patients with diabetes, the excess glucose outstrips resorptive capacity and appears in the urine (glycosuria). 13 In a healthy adult, this equates to a blood glucose concentration of approximately 11 mmol/L (200 mg/dL).
14 As much as 90% of the filtered glucose load is extracted in the S1 segment, and the remaining 10% is removed in the distal straight tubules (S2 and S3 segments) ( Figure 1 ). Until recently, the mechanisms behind glucose reabsorption were poorly understood, although it was proposed as early as 1960 that glucose transmembrane flux could be achieved through the coupling of glucose transport with that of sodium. 15 Since the start of the 20 th century, phlorizin, a toxic 2'-glucoside of phloretin, has been known to increase glycosuria, and has been used in the study of renal function. 16, 17 During the 1930s, phlorizin was used in non-invasive human experiments that revealed some of the fundamental mechanisms of renal hemodynamics and metabolic transport. 18 In the 1950s, studies delineated phlorizin's mechanism of action on inhibition of glucose transport in the kidney and small intestine at the cellular and molecular levels. Renal micropuncture studies conducted with phlorizin in the 1970s showed that the transporter was located in the brush border of the proximal tubule, and that sodium was required for the renal absorption of glucose. 11, 19, 20 Studies performed since then confirmed that phlorizin is a competitive inhibitor of glucose transport, with a binding affinity for the transporter that is 1000-to 3000-fold greater than that of glucose. 21 The rabbit homolog of the human type 1 sodium-glucose transporter (SGLT1), which is coded by the SLC5A gene, was the first mammalian cotransporter carrier protein to be identified, cloned, and sequenced. 
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0% glucose Figure 1 . Summary of glucose reabsorption from the lumen of the nephrons. Glucose concentration in the glomerular filtrate reflects plasma concentration. In most normal healthy subjects, the majority of glucose reabsorption is believed to occur in the early part of the proximal tubule.
SGLT2 INHIBITORS
The antidiabetic properties of phlorizin were investigated in the 1980s. In partially pancreatectomized rats, phlorizin increased glucose secretion in urine and this was associated with a normalizing of plasma glucose, without inducing hypoglycemia. 17 hepatic glucose production and glucose utilization rate were also observed in streptozotocininduced diabetic rats 26, 28 A summary of the status of inhibitor development is provided in Table 2 . One aspect of SGLT2 inhibition that has been raised as a potential issue of safety concern is that of glycosuria, which could predispose patients to increased urinary tract infections (UTI).
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The extent to which increases in infection will
occur has yet to be established. There have been some reports of infection in clinical studies. 60, 61 However, a study that reviewed risk factors for developing UTIs in women with diabetes observed that glucosuria was not a significant contributing factor. although SGLT2 deletion in animal models appears to improve glucose homeostasis and preserve pancreatic β-cell function. 63 We did not find any recorded evidence of an increased disposition to urinary tract or vulvovaginal infections, although identification and study of these subjects is difficult due to the rarity of the disease. Clearly, clinical development programs will need to address the concern of a possible increased risk of UTI. 
